
MERS vaccine safe and immunogenic in first-in-human trial
A DNA vaccine for MERS-CoV was demonstrated to be well-tolerated and immunogenic in a Phase I, first-in-human trial.
A DNA vaccine for MERS-CoV was demonstrated to be well-tolerated and immunogenic in a Phase I, first-in-human trial.
In this interview we speak to Vineet Menachery about his recent talk at the Microbiology Society’s Annual Conference (8–11 April, Belfast, UK) suggesting that CoV emergence is more complicated than receptor binding alone.
Public Health England have confirmed that an individual has been diagnosed with MERS in England
A case of Middle East Respiratory Syndrome has been reported to the WHO by the United Arab Emirates.
Editor, Martha Powell, takes a closer look at MERS, Nipah and Lassa; considering their impact on populations thus far and why medical countermeasures against them are so urgently required.